Literature DB >> 3724060

Monoclonal antibodies to titin in conjunction with antibodies to desmin separate rhabdomyosarcomas from other tumor types.

M Osborn, C Hill, M Altmannsberger, K Weber.   

Abstract

Titin is a major constituent protein of sarcomeric muscles and is thought to give rise to an elastic filament component underlying the myofibrillar organization. Monoclonal antibodies to titin have been characterized on normal and pathological human material and on human cell lines in culture. A positive immunocytochemical reaction was restricted to sarcomeric muscles and did not occur on visceral or vascular smooth muscles or on various nonmuscle tissues. When different tumor types were examined titin antibodies reacted solely with rhabdomyosarcomas and did not react with leiomyosarcoma or leiomyoma, or with the nonmuscle tumor types tested. In rhabdomyosarcomas a noticeably smaller population of cells were positive with antibodies to titin than with antibodies to desmin showing that individual cells within a rhabdomyosarcoma achieve different degrees of myogenic differentiation. The results reinforce the use of desmin as a marker for muscle sarcomas and show that a positive identification of rhabdomyosarcoma can be achieved by immunocytochemistry with the parallel use of desmin and titin antibodies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3724060

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

1.  Diagnosis of rhabdomyosarcomas with HHF35, a monoclonal antibody directed against muscle actins.

Authors:  R A Schmidt; R Cone; J E Haas; A M Gown
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

2.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.

Authors:  S Gattenloehner; A Vincent; I Leuschner; S Tzartos; H K Müller-Hermelink; T Kirchner; A Marx
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  HHF35, a muscle actin-specific monoclonal antibody. II. Reactivity in normal, reactive, and neoplastic human tissues.

Authors:  T Tsukada; M A McNutt; R Ross; A M Gown
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

4.  Undifferentiated sarcoma of the sellar region.

Authors:  Branavan Manoranjan; Luis V Syro; Bernd W Scheithauer; Leon D Ortiz; Eva Horvath; Fateme Salehi; Kalman Kovacs; Michael D Cusimano
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

5.  The cardiac isoform of alpha-actin in regenerating and atrophic skeletal muscle, myopathies and rhabdomyomatous tumors: an immunohistochemical study using monoclonal antibodies.

Authors:  Roland Moll; Hans-Jürgen Holzhausen; Hans-Dieter Mennel; Caecilia Kuhn; Renate Baumann; Christiane Taege; Werner W Franke
Journal:  Virchows Arch       Date:  2006-05-20       Impact factor: 4.064

6.  Soft tissue tumors of the anorectum: rare, complex and misunderstood.

Authors:  Mohammed O Nassif; Nora H Trabulsi; Kelli M Bullard Dunn; Ayoub Nahal; Ari-Nareg Meguerditchian
Journal:  J Gastrointest Oncol       Date:  2013-03

7.  Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II. Rhabdomyosarcomas.

Authors:  O Skalli; G Gabbiani; F Babaï; T A Seemayer; G Pizzolato; W Schürch
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

8.  Replicating myoblasts express a muscle-specific phenotype.

Authors:  S J Kaufman; R F Foster
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  Biosynthesis of titin in cultured skeletal muscle cells.

Authors:  W B Isaacs; I S Kim; A Struve; A B Fulton
Journal:  J Cell Biol       Date:  1989-11       Impact factor: 10.539

10.  The organization of titin filaments in the half-sarcomere revealed by monoclonal antibodies in immunoelectron microscopy: a map of ten nonrepetitive epitopes starting at the Z line extends close to the M line.

Authors:  D O Fürst; M Osborn; R Nave; K Weber
Journal:  J Cell Biol       Date:  1988-05       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.